Advertisement
Advertisement
U.S. Markets open in 9 hrs 20 mins
Advertisement
Advertisement
Advertisement
Advertisement

Pharmagreen Biotech Inc. (PHBI)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0065+0.0011 (+19.27%)
At close: 02:34PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0055
Open0.0060
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0045 - 0.0065
52 Week Range0.0010 - 0.0270
Volume368,000
Avg. Volume284,251
Market Cap2.504M
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-0.0260
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Pharmagreen Appoints Tyrell Crosby, a Professional Athlete, as Its Honorary Sports Ambassador

    CARSON CITY, NV, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), (“Pharmagreen” or the “Company”) is pleased to announce that Mr. Tyrell Crosby, a professional NFL player, has joined the Pharmagreen team to be an Honorary Sports Ambassador for Pharmagreen’s NutraMax Genomic Supplement product line. Tyrell will attend gatherings, trade shows, and other scheduled events selected by Pharmagreen, and will provide his endorsement of NutraMax products

  • GlobeNewswire

    PHBI Pharmagreen Biotech Appoints Ethan Styles as Vice President of Product Research and Development

    CARSON CITY, NV, Sept. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Pharmagreen Biotech, Inc., (OTCQB: PHBI), (“Pharmagreen” or the “Company) is pleased to announce that Ethan Styles has joined the Pharmagreen team in the role of Vice President of Product Research and Development. Mr. Styles’ lifelong work with therapeutic plants, cannabis, medicinal plants and fungi, combined with years of personal studies in molecular biology, has provided Ethan with keen insight into the human health benef

  • GlobeNewswire

    PHBI Pharmagreen Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch

    CARSON CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Pharmagreen Biotech, Inc., (OTCQB: PHBI), (“Pharmagreen” or the “Company” is pleased to announce that it has developed its first formulated nutraceutical product and is in the process of organizing the retail sales distribution channels for its new product. The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms. Pharmagreen

Advertisement
Advertisement